An ageing population, rising antimicrobial resistance, and the ongoing threat of infectious and chronic diseases are placing immense pressure on our societies. A shift to a preventative approach is necessary for the efficiency and sustainability of our healthcare systems. Central to this shift is the often-underutilized tool of life-course immunization.
The vaccine roll out gives hope of a return to some form of normality, but current high COVID-19 infection numbers put the success of vaccination programmes at risk. Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences explain why.
A new study by the University of California, Davis has found that a third of Americans are either unlikely or hesitant to get a COVID-19 vaccine when it becomes available.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
AstraZeneca CEO Pascal Soriot spoke to Antonello Guerrera about the ongoing vaccine feud - with the Commission receiving 60% less than expected, raising tense questions about why.
Prime Minister Boris Johnson announced that he had done "everything possible" to prevent 100,000 COVID deaths, as the UK witnesses 50,099 fatalities in the space of 79 days.
New vaccine data from Israel suggests that the double-dose of Pfizer is performing at the expected rate of 95% efficiency - with the possibility that it is performing even better than that being further investigated.
In response to the AstraZeneca feud, EU officials are creating a "transparency mechanism" for vaccine exports - which would indirectly hold companies accountable for fulfilling their agreed contracts.
The company announced that their current vaccine can handle the South African COVID mutation - with plans to create an "additional booster dose" to see if they can create specific protections against emerging variants.
Tomorrow (26 January) the COVID 'O' meeting is expected to be a moment of decision-making about border policy, as the more infectious South African and Brazilian COVID mutations continue to circulate.
EU leaders are investigating why AstraZeneca are not following through with the pre-agreed number of vaccines for the Member States - taking a 60% cut to the expected amount.
Paul Bensley, Managing Director at X-on, discusses how patient communications could be the only way to solve complex logistical considerations for mass vaccination.
